The 5 most recent market catalysts affecting $GHRS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 65
Guggenheim Maintains Buy on GH Research, Raises Price Target to $40
Guggenheim analyst Eddie Hickman has raised the price target for GH Research (GHRS) from $34 to $40 while maintaining a 'Buy' rating. This action signals increased confidence from …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on GH Research, Raises Price Target to $39
Needham analyst Ami Fadia maintained a 'Buy' rating on GH Research and raised the price target from $32 to $39. This upward revision in the price target indicates increased confide…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 75
GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate
GH Research (GHRS) announced its Q2 earnings, reporting a loss of $(0.23) per share. This figure is significant because it beat the consensus analyst estimate of $(0.30) per share …
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 65
Wells Fargo Initiates Coverage On GH Research with Overweight Rating, Announces Price Target of $44
Wells Fargo analyst Benjamin Burnett initiated coverage on GH Research (GHRS) with an 'Overweight' rating and a $44 price target. This event is significant because it introduces a …
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 85
Why Is GH Research Stock Trading Higher on Thursday?
Eli Lilly's agreement to acquire AtaiBeckley for up to $3.80 billion has ignited a rally in other psychedelic therapy stocks, particularly GH Research and Definium Therapeutics. Th…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.